Nonacidic Farnesoid X Receptor Modulators.

As a cellular bile acid sensor, farnesoid X receptor (FXR) participates in regulation of bile acid, lipid and glucose homeostasis, and liver protection. Clinical results have validated FXR as therapeutic target in hepatic and metabolic diseases. To date, potent FXR agonists share a negatively ionizable function that might compromise their pharmacokinetic distribution and behavior. Here we report the development and characterization of a high-affinity FXR modulator not comprising an acidic residue.

[1]  T. Willson,et al.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.

[2]  Identification of novel farnesoid X receptor modulators using a combined ligand- and structure-based virtual screening , 2013 .

[3]  K. V. van Erpecum,et al.  Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. , 2012, Biochimica et biophysica acta.

[4]  B. Beno,et al.  A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design. , 2015, Journal of medicinal chemistry.

[5]  L. Steinman,et al.  Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis , 2016, Proceedings of the National Academy of Sciences.

[6]  H. Kumar,et al.  Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptors. , 2014, Molecular endocrinology.

[7]  S. Mudaliar,et al.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. , 2013, Gastroenterology.

[8]  S. Kullman,et al.  Exposure to the synthetic FXR agonist GW4064 causes alterations in gene expression and sublethal hepatotoxicity in eleutheroembryo medaka (Oryzias latipes). , 2010, Toxicology and applied pharmacology.

[9]  G. Costantino,et al.  Molecular dynamics simulation of the ligand binding domain of farnesoid X receptor. Insights into helix-12 stability and coactivator peptide stabilization in response to agonist binding. , 2005, Journal of medicinal chemistry.

[10]  A. Carino,et al.  Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands. , 2014, Journal of medicinal chemistry.

[11]  L. Weber,et al.  Synthesis of Imidazo[1,2‐a] Annulated Pyridines, Pyrazines, and Pyrimidines by a Novel Three‐Component Condensation. , 1998 .

[12]  Shawn P Williams,et al.  Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. , 2008, Bioorganic & medicinal chemistry letters.

[13]  D. Steinhilber,et al.  NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor , 2015, Scientific Reports.

[14]  Stefan Westin,et al.  Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). , 2009, Journal of medicinal chemistry.

[15]  L. Adorini,et al.  Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine. , 2011, Bioorganic & medicinal chemistry.

[16]  R. Pellicciari,et al.  Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation. , 2014, Current topics in medicinal chemistry.

[17]  B. Kuhn,et al.  Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties. , 2011, Bioorganic & medicinal chemistry letters.

[18]  G. Schneider,et al.  Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist. , 2014, Journal of medicinal chemistry.

[19]  A. Moschetta,et al.  Review Nuclear Receptor Signaling | The Open Access Journal of the Nuclear Receptor Signaling Atlas Deciphering the nuclear bile acid receptor FXR paradigm , 2022 .

[20]  Yanping Xu.  Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases. , 2016, Journal of medicinal chemistry.

[21]  Ewgenij Proschak,et al.  Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery. , 2017, Journal of medicinal chemistry.

[22]  M. Trauner,et al.  Bile acid transporters and regulatory nuclear receptors in the liver and beyond , 2013, Journal of hepatology.

[23]  B. M. Forman,et al.  Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response , 2008, Hepatology.

[24]  S. Fiorucci,et al.  Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. , 2010, Current medicinal chemistry.

[25]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[26]  Wei Zhang,et al.  Biased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors , 2014, Journal of medicinal chemistry.

[27]  A. Carino,et al.  Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists , 2016, Scientific Reports.

[28]  L. Weber,et al.  Synthesis of Imidazo[1,2-a] annulated Pyridines, Pyrazines and Pyrimidines by a Novel Three-Component Condensation , 1998 .

[29]  Manfred Schubert-Zsilavecz,et al.  Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. , 2012, Future medicinal chemistry.

[30]  M. Schubert-Zsilavecz,et al.  Medicinal chemistry and pharmacological effects of Farnesoid X Receptor (FXR) antagonists. , 2014, Current topics in medicinal chemistry.

[31]  A. Moschetta,et al.  Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders. , 2016, Journal of medicinal chemistry.

[32]  D. Thompson,et al.  A formulation-enabled preclinical efficacy assessment of a farnesoid X receptor agonist, GW4064, in hamsters and cynomolgus monkeys. , 2011, Journal of pharmaceutical sciences.

[33]  Dennis A. Smith.  Metabolism, pharmacokinetics and toxicity of functional groups : impact of chemical building blocks on ADMET , 2010 .

[34]  L. Moore,et al.  Identification of a chemical tool for the orphan nuclear receptor FXR. , 2000, Journal of medicinal chemistry.